Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-220.1%+883,806pp-204.5%+507,474pp-191,982.5%+275,729pp-667,654.5%-667,006pp-884,026.1%-883,436pp
Returns
Return on invested capital-51.1%+7.0pp-40.9%+40.9pp-62.9%+10.4pp-56.5%-5.8pp-58.2%-9.3pp
Efficiency
Asset turnover0.2×0.2×+0.2×0.0×0.0×0.0×
Liquidity
Current ratio9.3×-3.0×9.4×-5.5×8.4×-8.9×8.7×-19.7×12.4×-20.3×
Leverage
Debt-to-equity0.0×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$6.64-21.2%$8.73-7.8%$6.57-33.9%$7.53-29.3%$8.43-30.9%
Valuation
Market capitalization$602.22M+215%$428.51M+66.4%$405.84M-32.1%$185.3M-84.0%$149.56M-90.5%
Price / sales6.8×-8,306×-6,954×3,382×-13,218×5,615.1×+5,558×6,502.5×+6,426×
Price / book1.3×+0.9×0.8×+0.3×1.1×0.0×0.4×-1.5×0.3×-2.3×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do 4D Molecular Therapeutics's ratios come from?
Every ratio is computed from 4D Molecular Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.